← back to search

Qin Lin

Zhongshan Hospital of Xiamen University · CN
Area of research
Oncology · Otorhinolaryngology
Research interest
Research interests include Head and Neck Cancer Studies, Esophageal Cancer Research and Treatment, Cancer Immunotherapy and Biomarkers, and Medical Imaging Techniques and Applications.
h-index
41
citations
7,271
works
280
NIH funding
primary concept
Medicine
email

Recent publications

FAP-targeted radioligand therapy with <sup>68</sup>Ga/<sup>177</sup>Lu-DOTA-2P(FAPI)<sub>2</sub> enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
Journal for ImmunoTherapy of Cancer 2025cited by 24position: middledoi
Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
Clinical Cancer Research 2025cited by 6position: middledoi
Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
Cancer Research 2025cited by 5position: middledoi
Targeted suppression of glioma by ultralow-dose x-ray-induced photodynamic therapy and gold-based nanoclusters in preclinical models.
2025cited by 3position: contributordoi
68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study.
2025cited by 3position: contributordoi
Induction Camrelizumab and Modified TPF (Nab-Paclitaxel, Cisplatin, and S-1) in Locoregionally Advanced Nasopharyngeal Carcinoma.
2025cited by 2position: contributordoi
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy.
2025cited by 2position: contributordoi
Data from Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
2025cited by 1position: contributordoi
Proteomics Combined with N-Glycoproteomics to Explore the Pathogenesis of Nasopharyngeal Carcinoma.
2025cited by 0position: contributordoi
Supplementary Figure S2 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Data from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Material S1 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Figure S5 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Figures 1 from Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
2025cited by 0position: contributordoi
Supplementary Table S1 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Tables 1 from Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
2025cited by 0position: contributordoi
Supplementary Figure S4 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Figure S3 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Table S2 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Figure S6 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Figure S1 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Supplementary Table S3 from &lt;sup&gt;68&lt;/sup&gt;Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study
2025cited by 0position: contributordoi
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
Oral Oncology 2024cited by 22position: middledoi
Development and Validation of Deep Learning Model for Intermediate-Stage Hepatocellular Carcinoma Survival with Transarterial Chemoembolization (MC-hccAI 002): a Retrospective, Multicenter, Cohort Study
Journal of Cancer 2024cited by 4position: middledoi
Prediction of Survival in Patients With Esophageal Cancer After Immunotherapy Based on Small-Size Follow-Up Data.
2024cited by 1position: contributordoi
Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
Journal of Nuclear Medicine 2023cited by 95position: middledoi
Clinical Evaluation of<sup>68</sup>Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin α<sub>v</sub>β<sub>3</sub>in Various Cancer Types
Journal of Nuclear Medicine 2023cited by 57position: middledoi
Evaluation of the role of postoperative radiotherapy in locally invasive thymoma: A propensity-matched study based on the SEER database.
2023cited by 4position: contributordoi
A deep learning MRI-based signature may provide risk-stratification strategies for nasopharyngeal carcinoma.
2023cited by 2position: contributordoi
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Cancer Cell 2022cited by 558position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 21 papers (2019–2025)Hua Wu · The First Affiliated Hospital of Xiamen University13 papers (2021–2025)Yizhen Pang · The first affiliated hospital of Xiamen University13 papers (2021–2025)Liang Zhao · Xiamen University13 papers (2021–2025) · 13 papers (2021–2025)Haojun Chen · First Affiliated Hospital of Xiamen University13 papers (2021–2025)Yaqing Dai · First Affiliated Hospital of Xiamen University12 papers (2025–2025)Hui Zhou · Chengdu University of Traditional Chinese Medicine12 papers (2025–2025) · 12 papers (2025–2025)Wei Guo · First Affiliated Hospital of Xiamen University12 papers (2025–2025)Hao Fu · Chinese PLA General Hospital12 papers (2025–2025)Shan Zhong · First Affiliated Hospital of Xiamen University12 papers (2025–2025)Jianhao Chen · Jiangsu University of Science and Technology12 papers (2025–2025)Lingyu Yu · First Affiliated Hospital of Xiamen University12 papers (2025–2025)Jianyang Fang · Xiamen University12 papers (2025–2025)Yi Ding · Ministry of Education12 papers (2025–2025)Liang Zhao · National University of Singapore6 papers (2020–2025)Haojun Chen · Xiamen University6 papers (2020–2025)Long Sun · Kunming University of Science and Technology5 papers (2020–2025)Hua Wu · Xiamen University5 papers (2019–2023)